Logo

Xtrana Wins $400K NIH Grant

Aug 29, 2001

NEW YORK, Aug. 29 – Xtrana has received a $400,000 Phase I NIH grant to develop nanofluidic nucleic acid preparation components, the company announced Wednesday.

The work will be done in collaboration with researchers at the University of New Mexico and Sandia National Laboratory.

The research builds on Broomfield, Colo.-based Xtrana’s Xtra Bind non-silica-based nucleic acid extraction technology. The application for the nanofluidic technology is to let users run assay panels for infectious diseases and other agents at the site of sample collection, the company said.

Xtrana develops, manufactures, markets test kits to assess and diagnose disorders of the blood and vascular system.

Breaking News
The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.